Literature DB >> 6201071

An association between low maternal serum alpha-fetoprotein and fetal chromosomal abnormalities.

I R Merkatz, H M Nitowsky, J N Macri, W E Johnson.   

Abstract

An index case of "undetectable" maternal serum alpha-fetoprotein at 16 weeks in the first pregnancy of a 28-year-old woman was associated with birth of an infant with trisomy 18. This fortuitous finding stimulated a retrospective study of prenatally diagnosed chromosomal abnormalities. From among a series of 3,862 genetic amniocenteses, 32 cases of fetal autosomal trisomy were diagnosed for which corresponding maternal serum and amniotic fluid alpha-fetoprotein data could be retrieved. From a second laboratory, nine additional cases were added. The maternal serum alpha-fetoprotein levels expressed as multiples of the median were significantly lower in distribution for these 41 women than those from a group of normal matched control subjects (p less than 0.001). Since maternal age is shown to be a less than adequate predictor of autosomal trisomic birth, we proposed that a low level of maternal serum alpha-fetoprotein obtained through routine screening may prove to be valuable in improving the prenatal detection of these serious anomalies.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6201071     DOI: 10.1016/0002-9378(84)90530-1

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  57 in total

1.  Attitudes toward maternal serum screening in Chinese women with positive results.

Authors:  Sheau-Wen Jan; Chih-Ping Chen; Lian-Hua Huang; Fu-Yuan Huang; Chung-Chi Lan
Journal:  J Genet Couns       Date:  1996-12       Impact factor: 2.537

2.  Prenatal diagnosis by amniocentesis and chorionic villus biopsy.

Authors:  J L Reynolds
Journal:  Can Fam Physician       Date:  1986-01       Impact factor: 3.275

3.  The maternal plasma proteome changes as a function of gestational age in normal pregnancy: a longitudinal study.

Authors:  Roberto Romero; Offer Erez; Eli Maymon; Piya Chaemsaithong; Zhonghui Xu; Percy Pacora; Tinnakorn Chaiworapongsa; Bogdan Done; Sonia S Hassan; Adi L Tarca
Journal:  Am J Obstet Gynecol       Date:  2017-03-03       Impact factor: 8.661

4.  Management of abnormal serum markers in the absence of aneuploidy or neural tube defects.

Authors:  William T Schnettler; Michele R Hacker; Rachel E Barber; Sarosh Rana
Journal:  J Matern Fetal Neonatal Med       Date:  2012-03-26

5.  Pregnancy associated plasma protein-A2: a novel biomarker for Down syndrome.

Authors:  S Munnangi; S J Gross; R Madankumar; G Salcedo; S E Reznik
Journal:  Placenta       Date:  2014-08-12       Impact factor: 3.481

6.  Alphafetoprotein in midtrimester Down's syndrome fetal serum.

Authors:  M J Seller
Journal:  J Med Genet       Date:  1990-04       Impact factor: 6.318

7.  The patent of a screening test.

Authors:  J L Waurin
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

8.  Screening for Down's syndrome based on individual risk.

Authors:  M Lewis; M J Faed; P W Howie
Journal:  BMJ       Date:  1991-09-07

9.  The ethics of antenatal screening: lessons from Canute.

Authors:  Timothy M Reynolds
Journal:  Clin Biochem Rev       Date:  2009-11

10.  Prenatal diagnosis for paediatricians.

Authors:  Anne Summers
Journal:  Paediatr Child Health       Date:  2003-01       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.